Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press642CONGRESSES AND CONFERENCESСЪЕЗДЫ И КОНФЕРЕНЦИИРезолюция по итогам Совета экспертов по иммунотерапии распространенного рака мочевого пузыряNecciA.Russian Federation
Резолюция по итогам Совета экспертов по иммунотерапии распространенного рака мочевого пузыря
1. Каприн А.Д., Старинский В.В., Петрова Г.В. Состояние онкологической помощи населению России в 2015 году. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИРЦ» Минздрава России, 2016. 236 с. [Kaprin A.D., Starinskiy V.V., Petrova G.V. State of oncological care in Russia in 2015. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMIRTS” Minzdrava Rossii, 2016. 236 p. (In Russ.)]. Каприн А.Д., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2014 году (заболеваемость и смертность). М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИРЦ» Минздрава России, 2016. 250 p. [Kaprin A.D., Starinskiy V.V., Petrova G.V. Malignant tumors in Russia in 2014 (morbidity and mortality). Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMIRTS” Minzdrava Rossii, 2016. 250 p. (In Russ.)].Каприн А.Д., Старинский В.В., Петрова Г.В. Состояние онкологической помощи населению России в 2015 году. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИРЦ» Минздрава России, 2016. 236 с. [Kaprin A.D., Starinskiy V.V., Petrova G.V. State of oncological care in Russia in 2015. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMIRTS” Minzdrava Rossii, 2016. 236 p. (In Russ.)]. Каприн А.Д., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2014 году (заболеваемость и смертность). М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИРЦ» Минздрава России, 2016. 250 p. [Kaprin A.D., Starinskiy V.V., Petrova G.V. Malignant tumors in Russia in 2014 (morbidity and mortality). Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMIRTS” Minzdrava Rossii, 2016. 250 p. (In Russ.)].2. Носов Д.А., Болотина Л.В., Воробьев Н.А. и др. Практические рекомендации по лекарственному лечению рака мочевого пузыря. Злокачественные опухоли 2016;4(2): 338–42. [Nosov D.A., Bolotina L.V., Vorob’ev N.A. et al. Practical recommendations on drug therapy of bladder cancer. Zlokachestvennye opukholi = Malignant Tumors 2016;4(2):338–42. (In Russ.)].Носов Д.А., Болотина Л.В., Воробьев Н.А. и др. Практические рекомендации по лекарственному лечению рака мочевого пузыря. Злокачественные опухоли 2016;4(2): 338–42. [Nosov D.A., Bolotina L.V., Vorob’ev N.A. et al. Practical recommendations on drug therapy of bladder cancer. Zlokachestvennye opukholi = Malignant Tumors 2016;4(2):338–42. (In Russ.)].3. Galsky M.D., Hahn N.M., Rosenberg J. et al. Treatment of patients with metastatic urothelial cancer “unfit” for Cisplatin-based chemotherapy. J Clin Oncol 2011;29(17):2432–8. DOI: 10.1200/JCO.2011.34.8433. PMID: 21555688.Galsky M.D., Hahn N.M., Rosenberg J. et al. Treatment of patients with metastatic urothelial cancer “unfit” for Cisplatin-based chemotherapy. J Clin Oncol 2011;29(17):2432–8. DOI: 10.1200/JCO.2011.34.8433. PMID: 21555688.4. Necchi A., Sonpavde G., Lo Vullo S. et al. Nomogram-based prediction of overall survival in patients with metastatic urothelial carcinoma receiving first-line platinum-based chemotherapy: retrospective international study of invasive/advanced cancer of the urothelium (RISC). Eur Urol 2016:1–9. DOI: 10.1016/j.eururo.2016.09.042. PMID: 27726966.Necchi A., Sonpavde G., Lo Vullo S. et al. Nomogram-based prediction of overall survival in patients with metastatic urothelial carcinoma receiving first-line platinum-based chemotherapy: retrospective international study of invasive/advanced cancer of the urothelium (RISC). Eur Urol 2016:1–9. DOI: 10.1016/j.eururo.2016.09.042. PMID: 27726966.5. Bellmunt J., Théodore C., Demkov T. et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 2009;27(27):4454–61. DOI: 10.1200/JCO.2008.20.5534. PMID: 19687335.Bellmunt J., Théodore C., Demkov T. et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 2009;27(27):4454–61. DOI: 10.1200/JCO.2008.20.5534. PMID: 19687335.6. Herr H.W., Morales A. History of bacillus Calmette-Guerin and bladder cancer: an immunotherapy success story. J Urol 2008;179(1):53–6.Herr H.W., Morales A. History of bacillus Calmette-Guerin and bladder cancer: an immunotherapy success story. J Urol 2008;179(1):53–6.7. Chen D.S., Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity 2013;39(1):1–10. DOI: 10.1016/j.immuni.2013.07.012. PMID: 23890059.Chen D.S., Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity 2013;39(1):1–10. DOI: 10.1016/j.immuni.2013.07.012. PMID: 23890059.8. Chen D.S., Irving B.A., Hodi F.S. Molecular pathways: next-generation immunotherapy-inhibiting programmed death-ligand 1 and programmed death-1. Clin Cancer Res 2012;18(24):6580–7. DOI: 10.1158/1078-0432.CCR-12-1362. PMID: 23087408.Chen D.S., Irving B.A., Hodi F.S. Molecular pathways: next-generation immunotherapy-inhibiting programmed death-ligand 1 and programmed death-1. Clin Cancer Res 2012;18(24):6580–7. DOI: 10.1158/1078-0432.CCR-12-1362. PMID: 23087408.9. Rosenberg J.E., Hoffman-Censits J., Powles T. et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase II trial. Lancet 2016;387(10031):1909–20. DOI: 10.1016/S0140-6736(16)00561-4. PMID: 26952546.Rosenberg J.E., Hoffman-Censits J., Powles T. et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase II trial. Lancet 2016;387(10031):1909–20. DOI: 10.1016/S0140-6736(16)00561-4. PMID: 26952546.10. Loriot Y. Atezolizumab in platinumtreated locally advanced or metastatic urothelial carcinoma (mUC): updated OS, safety and biomarkers from the phase II IMvigor210 Study. ESMO 2016.Loriot Y. Atezolizumab in platinumtreated locally advanced or metastatic urothelial carcinoma (mUC): updated OS, safety and biomarkers from the phase II IMvigor210 Study. ESMO 2016.11. Bellmunt J. IMvigor210: updated analyses of first-line atezolizumab in cisplatinineligible locally advanced/metastatic urothelial carcinoma. ESMO 2016.Bellmunt J. IMvigor210: updated analyses of first-line atezolizumab in cisplatinineligible locally advanced/metastatic urothelial carcinoma. ESMO 2016.12. Rosenberg,J., Petrylak D., Abidoye O. et al. Atezolizumab in patients (pts) with locally-advanced or metastatic urothelial carcinoma (mUC): Results from a pivotal multicenter phase II study (IMvigor 210). Eur J Cancer 2015;51(Suppl 3):S720. DOI: 10.1016/S0959-8049(15)30073-3.Rosenberg,J., Petrylak D., Abidoye O. et al. Atezolizumab in patients (pts) with locally-advanced or metastatic urothelial carcinoma (mUC): Results from a pivotal multicenter phase II study (IMvigor 210). Eur J Cancer 2015;51(Suppl 3):S720. DOI: 10.1016/S0959-8049(15)30073-3.